Treatment and response in refractory depression: Results from a specialist affective disorders service

Journal of Affective Disorders

Volumn 81, Issue 1, 2004, Pages 49-53

  Kennedy, N ^a,b   Paykel, E S ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Affective disorders service; Antidepressant augmentation; Combination antidepressants; Electroconvulsive therapy; High dose antidepressants; Refractory depression; Treatment resistant depression

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; FLUOXETINE; IMIPRAMINE; LIOTHYRONINE; LITHIUM; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PHENELZINE; PINDOLOL; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG MEGADOSE; ELECTROCONVULSIVE THERAPY; FEMALE; HEALTH SERVICE; HUMAN; MALE; MEDICAL RECORD; MOOD DISORDER; MORBIDITY; PRIORITY JOURNAL; PSYCHOTHERAPY; RETROSPECTIVE STUDY; SEX RATIO; THERAPY RESISTANCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ELECTROCONVULSIVE THERAPY; ENGLAND; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, UNIVERSITY; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; MILIEU THERAPY; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT ADMISSION; PSYCHIATRIC DEPARTMENT, HOSPITAL; PSYCHOTHERAPY; REFERRAL AND CONSULTATION; SPECIALISM;

EID: 2942594052     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(03)00192-7     Document Type: Article

References (23)

1. American Psychiatric Association Practice guidelines for major depressive disorder in adults. Am. J. Psychiatry. 150(Suppl. 4):1993;1-26
2. Anderson I.M., Nutt D.J., Deakin J.F. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British association for psychopharmacology guidelines. J. Psychopharmacol. 14:2000;3-20
3. British Medical Association and Royal Pharmaceutical Society of Great Britain, 2001. British National Formulary. BMA and RPSGB, London.
4. Georgotas A., McCue R.E., Cooper T.B., Nagachandran N., Friedhoff A. Factors affecting the delay of antidepressant effect in responders to nortriptyline and phenelzine. Psychiatry Res. 28:1989;1-9
5. Guy, W., 1976. ECDEU Assessment Manual for Psychopharmacology, DHEW Publication No (ADM) 76-338. US Department of Health, Education and Welfare. National Institute of Mental Health, Rockville, MD.
6. Guy W. Clinical Global Impressions (CGI) scale. Task Force for the Handbook of Psychiatric Measures Handbook of Psychiatric Measures. 2000;100-102 American Psychiatric Association, Washington, DC
7. Hirschfeld R.M., Montgomery S.A., Keller M.B., Kasper S., Schatzberg A.F., Moller H.J., Healy D., Baldwin D., Humble M., Versiani M., Montenegro R., Bourgeois M. Social functioning in depression: a review. J. Clin. Psychiatry. 61:2000;268-275
8. Keller M.B., Klerman G.L., Lavori P.W., Fawcett J.A., Coryell W., Endicott J. Treatment received by depressed patients. JAMA. 248:1982;1848-1855
9. Kienke A.S., Rosenbaum J.F. Efficacy of venlafaxine in the treatment of severe depression. Depress. Anxiety. 12(Suppl. 1):2000;50-54
10. Kotin J., Post R.M., Goodwin F.K. Drug treatment of depressed patients referred for hospitalisation. Am. J. Psychiatry. 130:1973;1139-1141
11. O'Brien S., McKeon P., O'Regan M. The efficacy and tolerability of combined antidepressant treatment in different depressive subgroups. Br. J. Psychiatry. 162:1993;363-368
12. Paykel E.S., Priest R.G. Recognition and management of depression in general practice: consensus statement. Br. Med. J. 305:1992;1198-1202
13. Price L.H., Carpenter L.L., Rasmussen L.A. Drug combination strategies. Amsterdam J.D., Hornig M., Nierenberg A.A. Treatment-Resistant Mood Disorders. 2001;194-222 Cambridge Univ. Press, Cambridge, UK
14. Prudic J., Haskett R.F., Mulsant B., Malone K.M., Pettinati H.M., Stephens S., Greenberg R., Rifas S.L., Sackeim H.A. Resistance to antidepressant medications and short-term clinical response to ECT. Am. J. Psychiatry. 153:1996;985-992
15. Razani J., White K.L., White J., Simpson G., Sloane R.B., Rebal R., Palmer R. The safety and efficacy of combined amitriptyline and tranylcypramine antidepressant treatment. Arch. Gen. Psychiatry. 40:1983;657-661
16. Schatzberg A.F., Cole J.O., Cohen B.M. Survey of depressed patients who have failed to respond to treatment. Davis J.M., Maas J.W. The Affective Disorders. 1983;73-86 American Psychiatric Press, Washington, DC
17. Scott J. Chronic depression. Br. J. Psychiatry. 153:1988;287-297
18. Simpson G.M., Lee J.H., Cuculic Z., Kellner R. Two dosages of imipramine in hospitalized endogenous and neurotic depressives. Arch. Gen. Psychiatry. 33:1976;1093-1102
19. Spitzer R.L., Endicott J., Robins E. Research diagnostic criteria: rationale and reliability. Arch. Gen. Psychiatry. 35:1978;773-782
20. Stimson N., Agrawal N., Lewis G. Randomised controlled trials investigating pharmacological and psychological interventions for treatment-refractory depression. Systematic review. Br. J. Psychiatry. 181:2002;284-294
21. World Health Organization The ICD-10 Classification of Mental and Behavioural Disorders. 1992;WHO, Geneva
22. Young J.P.R., Lader M.H., Hughes W.C. Controlled trial of trimipramine, monoamine oxidase inhibitors and combined treatment in depressed outpatients. Br. Med. J. 279:1979;1315-1317
23. Young W.F. Jr., Laws E.R. Jr., Sharbrough F.W., Weinshilboum R.M. Human monoamine oxidase. Lack of brain and platelet correlation. Arch. Gen. Psychiatry. 43:1986;604-609